Esta página foi traduzida automaticamente e a precisão da tradução não é garantida. Por favor, consulte o versão em inglês para um texto fonte.

GIM27-THERapy: a Study to Describe the Effectiveness of Tucatinib in Combination With Capecitabine and Trastuzumab in the Treatment of Metastatic HER-2 Positive Breast Cancer Patients in Real World Setting (THERapy)

6 de maio de 2026 atualizado por: Fondazione Oncotech

Non-interventional, Multicentric, Prospective, Observational Study to Describe the Effectiveness of Tucatinib in Combination With Capecitabine and Trastuzumab in the Treatment of Metastatic HER-2 Positive Breast Cancer Patients in Real World Setting

Non-interventional, multicenter, prospective observational study of tucatinib-trastuzumab capecitabine administered according to the standard local clinical practice following approved SmPC indication and dose.

About 300 Her2 positive metastatic breast cancer patients who are candidate to tucatinib treatment in real world setting including patients previously treated with trastuzumab, pertuzumab, T-DM1, T-DXd as per authorized therapy setting and NPP/EAP ongoing program.

Primary Objective:

To assess the treatment safety and effectiveness as measured by investigator criteria in metastatic breast cancer patients within the real-world setting treated with tucatinib in combination with trastuzumab and capecitabine according to standard local clinical practice following approved Summary of Product Characteristics (SmPC) indication and dose.

The primary purpose of this study is to evaluate the real word effectiveness of the combination therapy "tucatinib/trastuzumab/capecitabine" in mBC patients according to the approved SmPC indication and dose in the real-world setting. Patients with human epidermal growth factor receptor 2 (HER2)- positive metastatic breast cancer who have disease progression after therapy with multiple HER2-targeted agents have limited treatment options. HER2 is a transmembrane tyrosine kinase receptor that mediates cell growth, differentiation, and survival. HER2 is overexpressed in approximately 20% of breast cancers. Both antibody and small-molecule drugs that target HER2 and block its tyrosine kinase activity has been demonstrated to be effective in treating HER2-driven cancers. Tucatinib is an investigational, oral, highly selective inhibitor of the HER2 tyrosine kinase. On April 17, 2020, the Food and Drug Administration approved tucatinib in combination with trastuzumab and capecitabine, for adult patients with advanced unresectable or metastatic HER2- positive breast cancer, including patients with brain metastases, who have received one or more prior anti-HER2-based regimens in the metastatic setting. On 10 December 2020, the European Medicines Agency's (EMA) Committee for Medicinal Products for Human Use (CHMP) adopted a positive opinion, recommending the granting of a marketing authorization for Tukysa (tucatinib) in combination with trastuzumab and capecitabine for the treatment of adult patients with human epidermal growth factor receptor 2 (HER2)-positive locally advanced or metastatic breast cancer (BC) who have received at least two prior anti-HER2 treatment regimens. Tucatinib received a marketing authorization valid throughout the EU on February 2021. The approvals were based on the results of the phase II HER2CLIMB trial in which HER2-positive breast cancer patients, previously treated with trastuzumab, pertuzumab (Perjeta) and trastuzumab emtansine (T-DM1; Kadcyla), have been randomized to receive trastuzumab and capecitabine with either tucatinib or placebo (randomization 2:1).Among the 511 patients with measurable disease at baseline, an objective response was confirmed in 40.6% of patients in the tucatinib-combination group and 22.8% of patients in the placebo-combination group. The primary endpoint of the trial was PFS and the secondary end points comprised overall survival (OS), as well as confirmed objective response rate (ORR). Tucatinib demonstrated efficacy compared with placebo in PFS (7.8 months versus 5.6months) and OS (21.9 months versus 17.4 months). The most common adverse events in the tucatinib arm were diarrhea, palmar-plantar erythrodysesthesia syndrome, fatigue, nausea, and vomiting and transaminitis, even though typically low-grade, transient, and reversible. In addition, out of the ∼600 patients enrolled, 291 patients had brain metastases at baseline. Brain mets including those with active brain mets. Among patients with brain mets PFS at 1 y was 24,9% in the tucatinib combination group vs 0% in the placebo combination group, HR: 0.48;95% CI to 69%;p<0.0001 and median PFS was 7.6 and 5.4 respectively. This represents for many patients the availability of a new valuable therapeutic option especially where the occurrence of brain metastases is frequent. Based on the reported data and considering the clinical benefit of the therapy such as prolongation of PFS/OS, a prospective study on the efficacy and safety profile of the tucatinib in the real-world population can be very useful to follow the evolution of HER2- positive metastatic breast cancer with this promising treatment.

Visão geral do estudo

Status

Recrutamento

Condições

Descrição detalhada

study procedures:

Patients will be managed by their treating clinician without any additional instructions. The study will require no additional treatment procedures during patient visits. Patients meeting the selection criteria will be invited to participate in the study. Before any study-specific data are recorded, patients will be provided with all the study details prior to their decision to participate and will be requested to sign an informed consent form (ICF) prior to their participation in the study. Patient's baseline data, safety, and PS (evaluation according to the Eastern Cooperative Oncology Group [ECOG] score) will be

collected during the observation period (treatment with tucatinib- trastuzumab-capecitabine). Response and survival assessments will

be collected during the study and include symptomatic response and best response by the treating clinician's assessment, according to investigator criteria and the local clinical practice procedures. Safety, response, and survival will be assessed during the follow-up period (18 months post tucatinib treatment). Previous and subsequent non-tucatinib treatments that the patient will receive since the follow-up period will also be described.

Tipo de estudo

Observacional

Inscrição (Estimado)

300

Contactos e Locais

Esta seção fornece os detalhes de contato para aqueles que conduzem o estudo e informações sobre onde este estudo está sendo realizado.

Contato de estudo

Locais de estudo

  • Itália
      • Ancona, Itália
        • Ativo, não recrutando
        • AOU delle Marche
      • Aviano, Itália
        • Recrutamento
        • Irccs Centro Di Riferimento Oncologico (CRO)
        • Contato:
      • Bari, Itália
        • Recrutamento
        • IRCCS Istituto Tumori "Giovanni Paolo II"
        • Contato:
      • Barletta, Itália
        • Ainda não está recrutando
        • Mons. Dimiccoli P.O. Barletta
        • Contato:
      • Bergamo, Itália
        • Recrutamento
        • Asst Papa Giovanni Xxiii
        • Contato:
      • Caserta, Itália
      • Genova, Itália
        • Ativo, não recrutando
        • IRCCS Ospedale Policlinico San Martino
      • Milan, Itália
        • Recrutamento
        • IRCCS Ospedale San Raffaele
        • Contato:
      • Milan, Itália
        • Recrutamento
        • Istituto Europeo di Oncologia
        • Contato:
      • Misterbianco, Itália
        • Recrutamento
        • Humanitas Istituto Clinico Catanese
        • Contato:
      • Naples, Itália
      • Naples, Itália
        • Ativo, não recrutando
        • AOU Federico II
      • Naples, Itália
        • Recrutamento
        • Istituto Nazionale Tumori "Fondazione G. Pascale"
        • Contato:
      • Padova, Itália
        • Recrutamento
        • Istituto Oncologico Veneto I.R.C.C.S.
        • Contato:
      • Pagani, Itália
        • Ainda não está recrutando
        • P.O. "Andrea Tortora"
        • Contato:
      • Palermo, Itália
        • Ativo, não recrutando
        • A.O.U.P. "P. Giaccone"
      • Palermo, Itália
        • Ainda não está recrutando
        • ARNAS Civico - Palermo
        • Contato:
      • Palermo, Itália
      • Piacenza, Itália
        • Recrutamento
        • Ospedale "Guglielmo Da Saliceto"
        • Contato:
      • Pollena Trocchia, Itália
        • Ainda não está recrutando
        • A.S.L. Napoli 3 SUD - P.O. Apicella
        • Contato:
      • Rimini, Itália
      • Roma, Itália
        • Ainda não está recrutando
        • A.O.U. Policlinico "Umberto I"
        • Contato:
      • Roma, Itália
      • Roma, Itália
        • Ainda não está recrutando
        • Ospedale "Sandro Pertini" - A.S.L. Roma 2
        • Contato:
      • Rozzano, Itália
      • Salerno, Itália
      • San Giovanni Rotondo, Itália
      • Torino, Itália
        • Ainda não está recrutando
        • A.O.U. "Città della Salute e della Scienza di Torino" - P.O. Sant'Anna
        • Contato:
      • Trento, Itália
        • Ainda não está recrutando
        • Azienda Provinciale Servizi Sanitari di Trento - Ospedale Santa Chiara
        • Contato:
    • AV
      • Avellino, AV, Itália

Critérios de participação

Os pesquisadores procuram pessoas que se encaixem em uma determinada descrição, chamada de critérios de elegibilidade. Alguns exemplos desses critérios são a condição geral de saúde de uma pessoa ou tratamentos anteriores.

Critérios de elegibilidade

Idades elegíveis para estudo

  • Adulto
  • Adulto mais velho

Aceita Voluntários Saudáveis

Não

Método de amostragem

Amostra Não Probabilística

População do estudo

Her2 positive metastatic breast cancer patients who are candidate to tucatinib treatment in real world setting including patients previously treated with trastuzumab, pertuzumab, T-DM1, T-DXd as per authorized therapy setting and NPP/EAP ongoing program.

Descrição

Inclusion Criteria:

  • Women aged 18 years or older;
  • Metastatic breast cancer her2 positive;
  • Treatment and treated indication according to local label SmPC and reimbursement for tucatinib-trastuzumab capecitabine treatment;
  • At least 2 prior anti her2 treatment in any setting;
  • Written informed consent indicating that patients understand the purpose and procedures and are willing to participate in the study.

Exclusion Criteria:

  • Patients with diseases or significant clinical condition, according to the findings of the investigator, may interfere with the study evaluations;
  • Absence of any radiological assessment;
  • No data on tucatinib efficacy and safety.

Plano de estudo

Esta seção fornece detalhes do plano de estudo, incluindo como o estudo é projetado e o que o estudo está medindo.

Como o estudo é projetado?

Detalhes do projeto

Coortes e Intervenções

Grupo / Coorte
Her2 positive metastatic breast cancer patients
Her2 positive metastatic breast cancer patients who are candidate to tucatinib treatment in real world setting including patients previously treated with trastuzumab, pertuzumab, T-DM1, T-DXd as per authorized therapy setting and NPP/EAP ongoing program.

O que o estudo está medindo?

Medidas de resultados primários

Medida de resultado
Descrição da medida
Prazo
To assess the treatment safety and effectiveness as measured by investigator criteria in metastatic breast cancer patients
Prazo: From enrollment to the end of follow-up (18 months after tucatinib treatment)

Primary endpoint:

  • Real world Effectiveness of tucatinib/trastuzumab/capecitabine treatments will be collected according to SmPC indication and will include the evaluation in routine clinical practice of:
  • TTNT (time to next systemic treatment) defined as time from first administration of any study treatment ( i.e. tucatinib/trastuzumab/ capecitabine) to start of a subsequent systemic antineoplastic therapy or death whichever comes first
From enrollment to the end of follow-up (18 months after tucatinib treatment)

Colaboradores e Investigadores

É aqui que você encontrará pessoas e organizações envolvidas com este estudo.

Patrocinador

Fondazione Oncotech

Datas de registro do estudo

Essas datas acompanham o progresso do registro do estudo e os envios de resumo dos resultados para ClinicalTrials.gov. Os registros do estudo e os resultados relatados são revisados ​​pela National Library of Medicine (NLM) para garantir que atendam aos padrões específicos de controle de qualidade antes de serem publicados no site público.

Datas Principais do Estudo

Início do estudo (Real)

1 de julho de 2024

Conclusão Primária (Estimado)

1 de julho de 2029

Conclusão do estudo (Estimado)

1 de julho de 2029

Datas de inscrição no estudo

Enviado pela primeira vez

28 de abril de 2026

Enviado pela primeira vez que atendeu aos critérios de CQ

6 de maio de 2026

Primeira postagem (Real)

13 de maio de 2026

Atualizações de registro de estudo

Última Atualização Postada (Real)

13 de maio de 2026

Última atualização enviada que atendeu aos critérios de controle de qualidade

6 de maio de 2026

Última verificação

1 de maio de 2026

Mais Informações

Termos relacionados a este estudo

Termos MeSH relevantes adicionais

Outros números de identificação do estudo

  • GIM27-THERapy
  • 701 (Identificador de registro: RSO)

Plano para dados de participantes individuais (IPD)

Planeja compartilhar dados de participantes individuais (IPD)?

INDECISO

Informações sobre medicamentos e dispositivos, documentos de estudo

Estuda um medicamento regulamentado pela FDA dos EUA

Não

Estuda um produto de dispositivo regulamentado pela FDA dos EUA

Não

Essas informações foram obtidas diretamente do site clinicaltrials.gov sem nenhuma alteração. Se você tiver alguma solicitação para alterar, remover ou atualizar os detalhes do seu estudo, entre em contato com register@clinicaltrials.gov. Assim que uma alteração for implementada em clinicaltrials.gov, ela também será atualizada automaticamente em nosso site .

Se inscrever